Background-Few data exist to characterize the delivery of evidence-based medical therapy for outpatients with heart failure who have received implantable cardioverter-defibrillators or cardiac resynchronization therapy (CRT) for systolic dysfunction. Methods and Results-IMPROVE HF is a prospective study characterizing the management of 15 381 outpatients with systolic heart failure (left ventricular ejection fraction Յ35%) enrolled from 167 US cardiology practices. Data were abstracted for dose, type, and daily frequency for angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, ␤-blockers, and aldosterone antagonists. Target doses for each medication class were based on current guidelines. Patients with devices (implantable cardioverter-defibrillators, CRT with defibrillators, or CRT with pacemakers) more frequently received evidence-based medical therapy than did those without such devices, although treatment at or above target doses was low for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (implantable cardioverter-defibrillators 32.6%, CRT with pacemaker 30.7%, CRT with defibrillator 32.0%, no device 34.6%) and ␤-blockers (20.2%, 17.4%, 20.4%, and 15.3%, respectively). Fewer patients received aldosterone antagonists, although when used, doses were more frequently within the target dosing range (70.1%, 72.1%, 72.7%, and 76.5%, respectively). Multivariable models showed that use of CRT with defibrillators and CRT with pacemakers was significantly associated with delivery of ␤-blockers at or above target doses, but no device therapies were associated with angiotensin-converting enzyme inhibitor/angiotensin receptor blocker or aldosterone antagonist dosing. Conclusions-Patients treated with heart failure devices received evidence-based medical therapy at similar or greater frequency than did those without such devices. Patients with CRT with defibrillator or CRT with pacemaker devices were more likely to be treated with target doses of ␤-blockers than were patients not treated with device therapy. Doses of evidenced-based therapies remain significantly lower in clinical practice than in clinical trials. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT00303979. (Circ Heart Fail. 2010;3:596-605.) Key Words: heart failure Ⅲ drugs Ⅲ registries Ⅲ quality of care Ⅲ outpatient P rofessional society heart failure (HF) guidelines recommend the use of evidence-based medical therapy for all patients with current or prior symptoms of HF and reduced left ventricular ejection fraction in the absence of contraindications or intolerance. 1 These guidelines also recommend that Clinical Perspective on p 605 physicians make every effort to achieve the target doses of HF medical therapy shown to be effective in major clinical trials, as tolerated. Clinical trials of device therapy for HF
have required that patients be treated with HF medications before enrollment or have documented contraindications or intolerance to such therapies. 2, 3 Consequently, guidelinerecommended eligibility for device therapy emphasizes that patients receive optimal medical therapy for HF before and after receiving devices. 4 Few studies have examined whether medical therapies are appropriately used in practice settings other than clinical trials, particularly for patients with HF receiving both medical and device interventions. The objective of this study was to compare rates of evidence-based medical therapy provided to outpatients who had and had not received device therapy for systolic dysfunction and to determine the proportion of patients treated with guidelinerecommended target doses of medical therapies for HF.
Methods
IMPROVE HF is a prospective cohort study designed to examine the current management of patients with chronic HF or prior myocardial infarction and left ventricular systolic dysfunction. The overall objectives, study design, and methods have been described in previous publications. 5, 6 Patients eligible for participation in IMPROVE HF included those with an outpatient primary or secondary diagnosis of HF or prior myocardial infarction. Eligible patients were also required to have moderate to severe left ventricular systolic dysfunction confirmed qualitatively or by a quantitative left ventricular ejection fraction Յ35% measured by the most recent echocardiogram, nuclear multiple gated acquisition scan, contrast ventriculogram, or magnetic resonance imaging scan. Patients with a noncardiovascular medical condition associated with an estimated survival Ͻ1 year and those who had undergone cardiac transplantation were excluded. Outpatient single-specialty or multispecialty cardiology practices from all geographic regions of the United States were invited to participate in IMPROVE HF. Baseline data from the medical charts of eligible patients were collected by trained chart abstractors between 2005 and 2007. Patient data included demographic and clinical characteristics, medical history, previous cardiac treatments, New York Heart Association (NYHA) functional class, laboratory results, diagnostic tests, and current treatments, including both pharmacologic and device-based interventions. In addition, documented contraindications, intolerance, or other reasons for not prescribing evidence-based medical therapy (including economic, social, or religious reasons; noncompliance; and other reasons for refusal) were recorded. A representative sample of patient records was screened to yield a median of 90 patients for each practice (25th and 75th percentiles, 58 and 107 patients, respectively) with the methods previously described. 5 Definitions for each variable were prespecified, and trained abstractors collected patient data at each participating practice. Data quality was addressed by adhering to the data dictionary and by conducting regular, centralized retraining and testing for the abstractors. The average interrater reliability was good, with the statisticϭ0.82. In addition, 1.7 automated quality checks per data field were performed, and reports were generated monthly to ensure completeness and accuracy of the data submitted. Practice characteristics were collected by survey and completed by each practice at baseline. These surveys assessed geographic location, practice type, number of cardiologists, number of electrophysiologists, affiliation with a hospital or transplant center, presence of a device-based clinic, annual average number of patients treated, number of HF-devoted advanced practice nurse or physician assistant staff, and the presence or absence of a dedicated HF clinic. All practices participating in IMPROVE HF were approved by a local institutional review board or central institutional review board or received institutional review board waivers.
Evidence-Based Medical Therapies for HF
Patients eligible for medical therapy included only those who met the defined criteria for each specific care measure and for whom there were no documented contraindications, intolerance, refusal, or other rationale to explain why the guideline-recommended therapy was not provided. 5 Documentation of NYHA functional class is a prerequisite for aldosterone antagonist eligibility, and reported treatment rates and dosing include only patients with quantitative or qualitative documentation of NYHA functional class at a level consistent with the metric specification (NYHA Class III or IV). Target doses for medical therapy with angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), ␤-blockers, and aldosterone antagonists were selected to represent those used in large, randomized trials on which the guideline recommendations were based. The guideline-recommended target medication doses for agents in the ACEI, ARB, ␤-blocker, and aldosterone antagonist classes are presented in Table 1 . For the purpose of this study, target doses were assessed for both evidence-based, guidelinerecommended medications and other agents in the same class when frequently prescribed in clinical practice.
Statistical Methods
All statistical analyses were performed by independent biostatisticians under contractual agreement with Outcome Sciences, Inc (Cambridge, Mass). For this study, patients were grouped by the presence or absence of device therapy and type of device: cardiac resynchronization therapy with a pacemaker (CRT-P), CRT with a defibrillator (CRT-D), implantable cardioverter-defibrillator (ICD), or no device. Descriptive statistics for patient and practice characteristics were calculated and reported for all practices that completed a baseline practice survey. Statistics included the proportion, mean, standard deviation, and median for patient and practice characteristics. Reported percentages were based on the number of patients who received each therapy or received each therapy at or above target dose divided by the number of patients eligible for each therapy. The 
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Wilcoxon rank-sum test was calculated to assess differences in rates of evidence-based HF therapy between patients with and without devices. Univariate and multivariable generalized estimating equation (GEE) analyses were performed to determine whether use of ICD, CRT-P, or CRT-D device therapy was independently associated with delivery of evidence-based therapies at or above target doses compared with no device therapy. The GEE was used to control for the repeated results from practices and used an exchangeable correlation structure. All patient and practice characteristics listed in Tables 2 and 3 were modeled by univariate statistics with percent target dose as the dependent variable of interest. Patient and practice characteristics that were significant in the univariate model at PՅ0.10 were included in the multivariable model. Additionally, univariate and multivariable GEE models identified patient and practice characteristics independently associated with target dose therapy for the ACEI/ARB, ␤-blocker, and aldosterone antagonist medication classes. Sensitivity analyses were also performed to identify predictors of treatment at target doses, after assuming bestand worst-case scenarios for missing data for dose. The best-case scenario was defined as all patients with missing data classified as at or above the target dose, and the worst-case scenario assumed that all patients with missing dose data had been treated below the target dose. All analyses were completed with SAS statistical software, version 9.1 (SAS Institute, Cary, NC), and all statistical tests were 2 sided. Results were considered statistically significant when probability values were Ͻ0.05.
Role of the Sponsor
Medtronic provided financial and material support for the IMPROVE HF registry. The sponsor had no role or input into the selection of end points or quality measures used in the study. A contract research organization, Outcome Sciences, Inc (Cambridge, Mass), independently performed the practice-site chart abstractions for IMPROVE HF and is responsible for performing data checks, storing site-specific and aggregate data, and providing benchmarked quality-of-care reports to practice sites. The contract research organization received funding from Medtronic. Identified, individual practicesite data are not shared with either the steering committee or the sponsor. COPD indicates chronic obstructive pulmonary disease; CABG, coronary artery bypass graft; PVD, peripheral vascular disease; LVEF, left ventricular ejection fraction; SBP, systolic blood pressure; DBP, diastolic blood pressure; and BUN, blood urea nitrogen. Other abbreviations are as defined in text.
The authors had complete control and authority over the study design, manuscript preparation, and the decision to submit this manuscript to Circulation: Heart Failure for publication. The manuscript was submitted to Medtronic before submission for publication.
Results
This analysis was based on the medical records of 15 381 patients receiving care at 167 outpatient cardiology practices in the United States. Baseline characteristics of patients who received device therapy and those who did not are presented in Table 2 . Patients in the CRT-P group were older (75.2 years) than patients with a CRT-D or ICD device or those with no device therapy (68.8, 67.5, and 68.9 years, respectively; PϽ0.001). Significantly more patients with CRT-D and ICD devices were male (73.9% and 77.3%) compared with those treated with CRT-P (67.8%) and those not treated with devices (67.2%, PϽ0.001). A higher proportion of patients with an ICD had an ischemic HF etiology and a history of prior myocardial infarction. Mean left ventricular ejection fraction, systolic and diastolic blood pressures, and serum sodium levels were significantly lower for patients treated with CRT-P, CRT-D, or ICD compared with patients not treated with such devices. History of atrial fibrillation and QRS duration were significantly higher for patients receiving device therapy compared with patients not treated with devices.
Practice characteristics by device therapy group are shown in Table 3 . Patients treated with either CRT-D or an ICD were more likely to attend practices affiliated with teaching institutions, multispecialty practices, and practices with a dedicated HF clinic (PϽ0.001 for all comparisons). In addition, significantly more patients treated with CRT-D or ICD therapy received their care at outpatient practices with a higher mean number of cardiologists and a lower number of patients treated annually (PϽ0.001 and Pϭ0.004, respectively).
Medical Therapy
Differences in rates of medical therapies for systolic dysfunction by device therapy are presented in Table 4 . Use of ACEI/ARB therapy was significantly greater among patients with CRT-D and ICD devices than among patients receiving CRT-P or those not treated with devices (79.3% and 81.6% vs 76.4% and 78.7%, respectively; PϽ0.001). Approximately one third of eligible patients who received ACEI/ARB therapy, with or without a device, were treated at or above the target dose ( Figure 1 ). Among patients with a CRT-P, CRT-D, or ICD who were eligible for treatment with ␤-blockers, 81.7%, 88.9%, and 88.5%, respectively, received this medication, compared with 84.1% of patients not treated with devices (PϽ0.001). The proportion of patients administered ␤-blockers at or above the target dose was, however, quite low for all 4 groups of patients ( Figure 2 ).
Aldosterone antagonists were administered to 39.4%, 39.7%, and 37.9% of eligible patients with CRT-P, CRT-D, and ICD devices, respectively, compared with 32.8% of patients without devices who were eligible for this therapy (Pϭ0.020). Among patients with CRT-P, CRT-D, and ICD devices who were eligible for aldosterone antagonists, 72.1%, 72.7%, and 70.1%, respectively, were administered at least the target dose, whereas 76.5% of patients in the no-device group received the recommended dose or higher ( Figure 3 ). The findings were similar when the analysis of target doses of aldosterone antagonists included only those patients with NYHA Class III or IV HF.
Univariate analyses revealed that treatment with CRT-D or ICD was associated with decreased use of target doses of ACEI/ARB therapy (odds ratio [OR]ϭ0.84; 95% CI, 0.75 to 0.95; Pϭ0.004 and ORϭ0.89; 95% CI, 0.81 to 0.97; Pϭ0.008). Use of CRT-D or ICD therapy was significantly associated with delivery of ␤-blocker therapy at or above the target dose (ORϭ1.32; 95% CI, 1.15 to 1.52; PϽ0.0001 and ORϭ1.34; 95% CI, 1.21 to 1.50; PϽ0.0001). However, use of any device therapy was not associated with delivery of aldosterone antagonists at or above target doses. Multivariable GEE model analyses controlling for patient and practice 
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variables found that none of the device therapies were independently associated with greater or lesser use of ACEI/ ARB or aldosterone antagonist therapy at or above the target dose. In contrast, both CRT-P and CRT-D use was significantly associated with use of ␤-blocker therapy at or above the target dose (ORϭ1.54; 95% CI, 1.03 to 2.31; Pϭ0.0351; and ORϭ1.35; 95% CI, 1.07 to 1.71; Pϭ0.0115; Table 5 ). Sensitivity analysis to account for patients with missing dose data were consistent with these results, with 2 exceptions: in the best-case scenarios, only CRT-P use was associated with ␤-blocker use at or above the target dose; CRT-D was associated with use of below-target doses of aldosterone antagonists. Patient and practice characteristics independently associated with delivery of each therapy at or above target doses are shown in Table 5 . Patient characteristics associated with administration of ACEIs/ARBs at or above the target dose included race (black vs white), a history of diabetes or hypertension, increased systolic blood pressure, higher EF, and elevated serum sodium levels. On the other hand, a history of coronary artery bypass graft or percutaneous coronary intervention, atrial fibrillation, rales, and a higher resting heart rate at the most recent examination were associated with treatment at less than target doses of ACEIs/ ARBs. Patients treated at a transplant center were significantly more likely to receive ACEI/ARB therapy at or above target doses compared with those receiving care at practices not associated with a transplant center. The sensitivity analysis to investigate the effect of missing dose data showed that hypertension, a history of percutaneous coronary intervention, diabetes, elevated systolic blood pressure, and treatment at a transplant center remained significant. Diabetes, HF etiology of ischemic heart disease, increased systolic blood pressure, elevated serum potassium, treatment in an HF clinic, and a hospital-based practice were the only patient and practice characteristics significantly associated with increased delivery of target doses of ␤-blockers, whereas increasing age, prior coronary artery bypass graft, and a history of chronic obstructive pulmonary disease were associated with treatment at lower than target doses. Results of the sensitivity analysis were consistent with these results, with the exception of elevated potassium and history of chronic obstructive pulmonary disease. None of the patient or practice characteristics were significantly associated with administration of target doses of aldosterone antagonists. In the best- case scenario, diastolic blood pressure was associated with delivery of target dosing, and blood urea nitrogen was associated with below-target dosing of aldosterone antagonists. The worst-case scenario showed a significant association of diastolic blood pressure and age with below-target dosing, whereas treatment in the South was associated with delivery of at or above target dosing.
Discussion
Medical therapies are an essential component of management of systolic HF because of their proven ability to significantly reduce mortality. 7-10 Accordingly, national practice guidelines recommend use of certain medications for all stable patients with systolic HF in the absence of contraindications. 7 The strategy for administration of ACEIs, ARBs, and ␤-blockers in each of the major clinical trials was based not on patients' response to therapy but on their tolerance for up-titration of the dose over the course of several weeks until a prespecified target dose was achieved. Lower doses were prescribed only when target doses were not tolerated. Rates of achievement of target doses in these trials ranged from 58.6% in the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial to 64% in the Metoprolol Controlled-Release/Extended-Release Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF) and 84% in the Valsartan Heart Failure Trial (Val-HeFT). 10 -12 Although few clinical trials have evaluated the effectiveness of lower doses of ACEI, ARB, and ␤-blocker therapy, 13 current guidelines recommend that physicians should make every effort to achieve the target doses shown to be effective in major clinical trials. 7 The addition of device therapy to the armamentarium for treating patients with HF has been a significant advance. ICD therapy is estimated to provide an incremental reduction in all-cause mortality ranging from 23% to 31% when used in conjunction with evidence-based HF medical therapy. 14 Similarly, a recent meta-analysis of pooled data from 6 randomized, controlled trials of CRT for treatment of chronic, symptomatic left ventricular systolic dysfunction indicated that CRT was associated with a 28% reduction in all-cause mortality and a 37% reduction in new hospitalizations for exacerbation of HF. 15 Despite the significant benefits of device therapy, this intervention is not without risk and is associated with a small but important failure rate. 16 The 2008 recommendations from the American Heart Association, the American College of Cardiology, and the Heart Rhythm Society guidelines underscore this point when they state that device therapy should be used in the context of full application of medical therapy. 4 In patients treated with devices in the Second Multicenter Automated Defibrillator Implantation Trial (MADIT-II), 68% A ICD 20 were given ACEIs (use of ARBs not reported). 17 Ninety-four percent of patients in the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) were treated with ACEI or ARB therapy at the study initiation, although this declined to 86% by the end of the trial. Use of ACEIs in IMPROVE HF was somewhat better than in MADIT-II but not as high as in SCD-HeFT. Patients in IMPROVE HF who were treated with devices received ACEI or ARB therapy more often than did those not treated with devices, but only approximately one third received the recommended target doses. Achievement of target dose was similar for patients treated with ICD, CRT-P, and CRT-D and those not receiving a device. Thus, in clinical practice, target doses of ACEI/ARB therapy are achieved at rates Ϸ50% lower than reported in the pivotal trials. Use of ␤-blockers was more frequent in the IMPROVE HF group of patients treated with ICD and CRT-D at baseline (88.5% and 88.9%, respectively) than in either SCD-HeFT or MADIT-II (69% and 70%, respectively). This may reflect a generalized increased acceptance of ␤-blocker therapy between the time of these 2 ICD trials and IMPROVE HF. However, only Ϸ20% of eligible patients enrolled in IMPROVE HF who were treated with ICD, CRT-D, or CRT-P received ␤-blockers at or above recommended target doses, a rate that is approximately one third that reported by the pivotal ␤-blocker clinical trials. Nonetheless, target doses were used more frequently in patients receiving device therapy than in those without devices. The use of doses of ACEIs/ARBs and ␤-blockers that are lower than those shown to be efficacious in clinical trials and recommended in guidelines may expose patients to a greater risk of HF disease progression and mortality.
Although aldosterone antagonists were used for fewer than half of eligible patients in IMPROVE HF, more often for patients treated with a device (37.9% to 39.7%) than in those without 1 (32.8%), they were used more frequently than in SCD-HeFT (21%). However, among those treated with these agents in IMPROVE HF, Ͼ70% were at or above the target dose. The Randomized Aldactone Evaluation Study (RALES) did not report the number of patients who achieved the target dose of 25 mg daily, but the median dose was 26 mg/d. 18 CRT trials have also specified HF medical therapies required at the time of enrollment unless contraindicated or not tolerated. The Comparison of Medical Therapy, Pacing, and Defibrillation in Chronic Heart Failure (COMPANION) trial reported that ACEIs or ARBs were used for 90% of patients without contraindications, whereas 95% of patients enrolled in the Cardiac Resynchronization in Heart Failure (CARE-HF) trial received these therapies. 3, 19 In both studies, ACEI/ARB therapy was used much more frequently than observed in IMPROVE HF, in which only 79.3% of patients with CRT-D and 76.4% of patients with CRT-P were treated with ACEIs/ARBs at baseline, and only 32.0% and 30.7% of these patients, respectively, received target doses. ␤-Blockers were used for 68% of patients in COMPANION 19 and for 70% of those in CARE-HF, 19 compared with 81.7% (CRT-P) and 88.9% (CRT-D) of patients in IMPROVE HF who received CRT. In CARE-HF, 38% of patients taking ACEIs, 50% of patients taking aldosterone antagonists, and 39% of patients taking ␤-blockers received doses that were at least half of target. 19 Patients cared for at practices participating in IMPROVE HF were substantially more likely to be treated at or above target doses compared with those enrolled in CARE-HF.
The reasons that treatment with CRT-D and CRT-P device therapies were independently associated with delivery of ␤-blocker therapy at or above target doses cannot be directly ascertained. Patient preferences, prescribing physician factors, and presence or lack of coexisting medical illness may all play a role. The patient's clinical status, which may not have been fully captured in the medical records, could have presented a challenge to up-titrating medications and limited the ability to tolerate higher doses. Because HF guidelines emphasize the use of chronic optimal medical therapy before device placement, there may have been greater focus on medication dosing for these patients.
A number of patient and practice factors were associated with a greater frequency of target dosing for ACEI/ARB and ␤-blocker therapy. Higher systolic blood pressure was, not unexpectedly, associated with greater odds of target dosing of ACEIs/ARBs and ␤-blockers. The explanations behind some of the other associations are less clear and will require further study. Certain practice characteristics were also associated with dosing, suggesting that the practice environment may influence physician dosing of HF medications.
The findings from this study support previous research suggesting that there are opportunities to improve dosing of HF medications in patients with and without implanted devices. Ansari et al 20 observed substantial increases in the use of ␤-blocker therapy (from 33% to 67%) and achievement of target dose (from 0% to 43%) with the use of nurse facilitators trained to implement practice guidelines. Moyer-Knox et al 21 evaluated a nurse-managed telephone titration protocol and found that 96% of patients were successfully placed on ␤-blockers and 71% achieved the target dose of 25 mg BID. These results suggest that the most effective strategies to improve use of target doses of HF medications in outpatient clinical practices may be interventions that focus on aggressive follow-up and dose titration. Such interventions may include enhanced systems of care to better educate patients to expect dose up-titration even when their HF symptoms have improved or resolved, point-ofcare physician decision support for up-titration, and support for patient adherence to follow-up visits at regular intervals until target doses are achieved.
Limitations
The design of IMPROVE HF has some inherent limitations that may affect the interpretation of findings. Specifically, patient data were collected by medical chart review, which is dependent on the accuracy and completeness of documentation. It is possible that a proportion of patients who were reported to be eligible for any of the HF medications but who were not so treated may have had medical contraindications, physician rationales, or patient reasons precluding administration of the specific therapy that were not documented in medical records. Similarly, an undetermined number of patients may have refused specific medications or may have received these interventions after baseline data abstraction was completed. Medication use and dosing were based on information documented in the medical record; actual doses and adherence rates may have been different. Thus, this study may overestimate or underestimate the rates of compliance with guideline-recommended therapies. Also, it was not possible to distinguish between patients for whom up-titration was attempted but unsuccessful because of intolerance and patients for whom no attempts to up-titrate were made. Furthermore, specified medication dose was missing for a proportion of patients, from 4.9% for eligible patients with CRT-D devices and treated with ACEIs/ARBs to 13.0% of eligible patients with no devices who were treated with ␤-blockers. As a result, estimates of patients who were administered medications at or above recommended doses may be moderately over-or underestimated. Residual measured or unmeasured confounding variables may account for some or all of the observations in the multiple variable analysis. Duration of HF, time since device implantation, and time since the most recent HF hospitalization were unavailable, as these were inconsistently documented in the outpatient medical records. The patients seen in the IMPROVE HF practices may not be fully representative of the general outpatient population of HF patients. These patients were followed up in outpatient cardiology practices, and ascertainment bias may be attributed to this point of care.
Conclusions
Among outpatient cardiology practices participating in IMPROVE HF, the majority of patients were treated with ACEI/ARB and ␤-blocker therapy. Aldosterone antagonists were less frequently prescribed. Rates of evidence-based medical therapy for ACEIs/ARBs and ␤-blockers were, with few exceptions, higher for patients treated with device therapy than for patients not treated with devices. However, the prescribed doses of ACEI/ARB and ␤-blocker therapies were below guideline-recommended target dosing in the majority of patients. Approximately one third of patients who received ACEIs/ARBs were treated at or above the target dose for this therapy regardless of device treatment status. Patients with CRT-P and CRT-D, but not ICD, devices were more likely to receive target doses of ␤-blockers than were patients with no devices. Among eligible patients treated with aldosterone antagonists, the majority received the recommended target doses. These findings suggest that there are opportunities to further improve use of evidence-based medical therapy at recommended target doses for patients with and without device therapy for HF.
